142 related articles for article (PubMed ID: 32557125)
21. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
[TBL] [Abstract][Full Text] [Related]
22. Nilotinib-induced interstitial lung disease.
Go SI; Lee WS; Lee GW; Kang JH; Kang MH; Lee JH; Kim HG
Int J Hematol; 2013 Sep; 98(3):361-5. PubMed ID: 23877149
[TBL] [Abstract][Full Text] [Related]
23. Pioglitazone with imatinib in CML may reduce residual disease.
Brower V
Lancet Oncol; 2017 Feb; 18(2):e70. PubMed ID: 28089103
[No Abstract] [Full Text] [Related]
24. Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Stagno F; Stella S; Spitaleri A; Pennisi MS; Di Raimondo F; Vigneri P
Expert Rev Anticancer Ther; 2016; 16(3):273-8. PubMed ID: 26852913
[TBL] [Abstract][Full Text] [Related]
25. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
[TBL] [Abstract][Full Text] [Related]
26. BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.
Durand MJ; Hader SN; Derayunan A; Zinkevich N; McIntosh JJ; Beyer AM
Microcirculation; 2020 Oct; 27(7):e12625. PubMed ID: 32395853
[TBL] [Abstract][Full Text] [Related]
27. Bullous sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib: interphase cytogenetic detection of BCR-ABL- positive lesional cells.
Kaune KM; Baumgart M; Gesk S; Mitteldorf C; Baesecke J; Glass B; Haase D; Siebert R; Ghadimi BM; Neumann C; Emmert S
Arch Dermatol; 2008 Mar; 144(3):361-4. PubMed ID: 18347292
[TBL] [Abstract][Full Text] [Related]
28. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
29. Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.
Dragani M; Rege-Cambrin G; Ferrero D; Abruzzese E; Pregno P; Elena C; Cedrone M; Santoro M; Andreani G; Saglio G; Fava C
Leuk Lymphoma; 2019 Dec; 60(13):3330-3332. PubMed ID: 31161827
[No Abstract] [Full Text] [Related]
30. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Defuentes G; Bladé JS; Berets O
N Engl J Med; 2007 Oct; 357(15):1556-7; author reply 1557-8. PubMed ID: 17928609
[No Abstract] [Full Text] [Related]
32. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
33. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
[TBL] [Abstract][Full Text] [Related]
34. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Ikuta K; Torimoto Y; Jimbo J; Inamura J; Shindo M; Sato K; Tokusashi Y; Miyokawa N; Kohgo Y
Int J Hematol; 2005 Nov; 82(4):343-6. PubMed ID: 16298828
[TBL] [Abstract][Full Text] [Related]
35. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
Hadzijusufovic E; Albrecht-Schgoer K; Huber K; Hoermann G; Grebien F; Eisenwort G; Schgoer W; Herndlhofer S; Kaun C; Theurl M; Sperr WR; Rix U; Sadovnik I; Jilma B; Schernthaner GH; Wojta J; Wolf D; Superti-Furga G; Kirchmair R; Valent P
Leukemia; 2017 Nov; 31(11):2388-2397. PubMed ID: 28757617
[TBL] [Abstract][Full Text] [Related]
36. [Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].
Yamaguchi M; Konishi I
Rinsho Ketsueki; 2003 Apr; 44(4):254-6. PubMed ID: 12784659
[TBL] [Abstract][Full Text] [Related]
37. Lichen planopilaris-like eruption during treatment with tyrosine kinase inhibitor nilotinib.
Leitão JR; Valente NY; Kakizaki P; Veronez IS; Pires MC
An Bras Dermatol; 2016; 91(5 suppl 1):45-47. PubMed ID: 28300891
[TBL] [Abstract][Full Text] [Related]
38. [Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Burchert A; Neubauer A
Internist (Berl); 2011 Mar; 52(3):283-93; quiz 294-5. PubMed ID: 21253680
[TBL] [Abstract][Full Text] [Related]
39. [The clinical analysis of frontline nilotinib vs imatinib therapies for newly diagnosed chronic myeloid leukemia in chronic phase].
Yin H; Chen LF; Cui JK; Xiong YY; You Y; Zou P; Li WM
Zhonghua Nei Ke Za Zhi; 2017 Nov; 56(11):810-815. PubMed ID: 29136709
[No Abstract] [Full Text] [Related]
40. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Kantarjian H; Giles F; Wunderle L; Bhalla K; O'Brien S; Wassmann B; Tanaka C; Manley P; Rae P; Mietlowski W; Bochinski K; Hochhaus A; Griffin JD; Hoelzer D; Albitar M; Dugan M; Cortes J; Alland L; Ottmann OG
N Engl J Med; 2006 Jun; 354(24):2542-51. PubMed ID: 16775235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
